See more : Sequana Medical NV (SEQUA.BR) Income Statement Analysis – Financial Results
Complete financial analysis of Quoin Pharmaceuticals, Ltd. (QNRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quoin Pharmaceuticals, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DP Cap Acquisition Corp I (DPCS) Income Statement Analysis – Financial Results
- UNIQA Insurance Group AG (UQA.VI) Income Statement Analysis – Financial Results
- Kaname Kogyo Co.,Ltd. (6566.T) Income Statement Analysis – Financial Results
- Koninklijke Ahold Delhaize N.V. (AHODF) Income Statement Analysis – Financial Results
- Corteva, Inc. (CTVA) Income Statement Analysis – Financial Results
Quoin Pharmaceuticals, Ltd. (QNRX)
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -280.00K | 0.00 | -280.00K | 0.00 |
| Cost of Revenue | 103.44K | 103.64K | 104.12K | 104.77K | 227.06K | 125.72K | 104.22K | 89.13K | 18.27K |
| Gross Profit | -103.44K | -103.64K | -104.12K | -104.77K | -227.06K | -405.72K | -104.22K | -369.13K | -18.27K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 144.90% | 0.00% | 131.83% | 0.00% |
| Research & Development | 3.31M | 2.67M | 1.56M | 244.16K | 45.65K | 8.26M | 5.89M | 8.26M | 1.52M |
| General & Administrative | 6.07M | 6.58M | 4.50M | 1.43M | 1.51M | 7.97M | 4.20M | 7.97M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.07M | 6.58M | 4.50M | 1.43M | 1.51M | 7.97M | 4.20M | 7.97M | 1.06M |
| Other Expenses | 0.00 | 417.31K | -14.03M | -378.33K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.38M | 9.26M | 6.06M | 1.67M | 1.56M | 16.22M | 10.10M | 16.22M | 2.58M |
| Cost & Expenses | 9.38M | 9.26M | 6.06M | 1.67M | 1.56M | 16.22M | 10.10M | 16.22M | 2.60M |
| Interest Income | 692.82K | 95.75K | 1.37K | 47.02 | 0.00 | 0.00 | 0.00 | 0.00 | 1.03K |
| Interest Expense | 0.00 | 714.08K | 1.09M | 47.02K | 412.29K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 103.44K | 103.64K | 104.12K | 104.77K | 227.06K | 125.72K | 104.22K | 89.13K | 18.27K |
| EBITDA | -9.27M | -8.74M | -21.37M | -2.01M | -1.54M | -5.47M | -7.80M | -3.91M | -2.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Operating Income | -9.38M | -8.85M | -20.37M | -2.05M | -1.56M | 15.32M | 10.17M | 15.32M | -2.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Total Other Income/Expenses | 714.32K | -123.79K | -1.09M | -425.35K | 0.00 | 2.54M | -1.06M | 237.07K | -19.30K |
| Income Before Tax | -8.66M | -9.38M | -21.46M | -2.10M | -1.56M | 15.32M | 10.17M | 15.32M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| Income Tax Expense | 22.38K | -104.04K | -12.94M | -331.31K | 1.55M | -161.14K | -1.17M | 147.94K | -1.00 |
| Net Income | -8.69M | -9.28M | -8.52M | -1.76M | -1.56M | 15.32M | 10.17M | 15.32M | -2.62M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,470.36% | 0.00% | -5,470.36% | 0.00% |
| EPS | -9.64 | -22.97 | -322.49 | -88.10 | -440.29 | 7.10K | 5.45K | 10.08K | -2.11K |
| EPS Diluted | -9.64 | -22.97 | -322.49 | -88.10 | -440.29 | 7.10K | 5.45K | 10.08K | -2.11K |
| Weighted Avg Shares Out | 900.92K | 403.88K | 26.42K | 20.02K | 3.54K | 2.16K | 1.87K | 1.52K | 1.24K |
| Weighted Avg Shares Out (Dil) | 901.10K | 403.88K | 26.42K | 20.02K | 3.54K | 2.16K | 1.87K | 1.52K | 1.24K |
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter...
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is falling on Tuesday after the clinical-stage specialty pharmaceutical company announced details of a public offering for its shares. The public offering has Quoin Pharmaceuticals selling 4,062,500 shares of QNRX stock for $1.60 each.
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX). The trials focus on the...
PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan
NEW YORK, NY, December 13, 2023 – Quoin Pharmaceuticals (Nasdaq:QNRX) has received U.S. Food and Drug Administration (FDA) clearance to implement several protocol amendments to its two ongoing clinical trials for QRX003, which is a potential treatment for Netherton Syndrome, a rare...
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed to twice-daily from once-daily for both trials
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter...
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints
Source: https://incomestatements.info
Category: Stock Reports